Drexel University - Comprehensive, integrated academics enhanced by co-operative education, technology, and research opportunities. | Drexel University
Drexel University
Search events. View events.

All Categories

Click for help in using calendar displays. Print the contents of the current screen.
Display Format: 
Event Details
Notify me if this event changes.Add this event to my personal calendar.
Go Back
Development & Characterization of Minocycline-Releasing Drug Delivery Systems for Spinal Cord Repair
Start Date: 6/15/2016Start Time: 10:00 AM
End Date: 6/15/2016End Time: 12:00 PM

Event Description
BIOMED PhD Research Proposal

Title:
Development and Characterization of Minocycline-Releasing Drug Delivery Systems for Spinal Cord Repair

Speaker:
Zhicheng Wang, PhD Candidate, School of Biomedical Engineering, Science and Health Systems

Advisor:
Yinghui Zhong, PhD, Assistant Professor, School of Biomedical Engineering, Science and Health Systems

Abstract:
Traumatic spinal cord injury (SCI) causes partial or complete loss of sensory, motor, and autonomic functions below the injury site. Patients with SCI suffer lifelong disability and require continuous physical and medical care. It is a leading cause of permanent disability in young adults. The initial trauma is followed by a wave of secondary injury cascades that leads to a cavity many times bigger than the initial lesion and often causes deleterious functional loss. Many mechanisms contribute to the secondary injury cascades following traumatic spinal cord injury (SCI). However, most current treatment strategies only target one or a few elements in the injury cascades, and have been largely unsuccessful in clinical trials.

Minocycline hydrochloride (MH) is a highly promising therapeutic intervention for SCI because it has been shown to target a broad range of secondary injury mechanisms via its anti-inflammatory, anti-oxidant, and anti-apoptotic properties. However, MH is only neuroprotective at high concentrations. The inability to translate the high doses of MH used in experimental animals to tolerable doses in human patients limits its clinical efficacy.

In addition, the duration of MH treatment is limited because long-term systemic administration of high doses of MH has been shown to cause liver toxicity and even death. We have developed a drug delivery system in the form of hydrogel loaded with polysaccharide-MH complexes self-assembled by metal ions for controlled MH release. This drug delivery system can be injected into the intrathecal space for non-invasive local delivery of MH with sufficient dose and duration. We show that local delivery of MH was effective in reducing secondary injury and promoting locomotor functional recovery.
Contact Information:
Name: Ken Barbee
Phone: 215-895-1335
Email: barbee@drexel.edu
Biomed logo
Location:
Bossone Research Center, Room 709, located at 32nd and Market Streets.
Audience:
  • Undergraduate Students
  • Graduate Students
  • Faculty
  • Staff

  • Display Month:

    Advanced Search (New Search)
    Date Range:
    Time Range:
    Category(s):
    Audience: 

    Special Features: 

    Keyword(s):
    Submit
    Select item(s) to Search
    Select item(s) to Search
    Select item(s) to Search
    Select item(s) to Search